At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 2,004 enrolled
Drug / intervention
Ticagrelordrug
Likely dose
Ticagrelor 90mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Single Arm, Open Label, Phase IV Study to Evaluate Safety and to Describe the Incidence of Major Cardiovascular Events of Ticagrelor in Chinese Patients With Acute Coronary Syndrome(ACS)
In Brief
A Phase 4 clinical trial evaluating Ticagrelor for Acute Coronary Syndrome. Completed, enrolled 2,004 participants across 39 sites.
Detailed Summary
A multicenter, single arm, open label, Phase IV study to evaluate safety and to describe the incidence of major cardiovascular events of ticagrelor in Chinese patients with acute coronary syndrome
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Coronary Syndrome
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 2013
Enrollment StartJun 2013
Primary CompletionSep 2015
TodayJul 2026
First PostedJun 6, 2013
Enrollment StartJun 26, 2013
Primary CompletionSep 30, 2015
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 13.1 years ago
Interventions
Ticagrelordrug
90mg/tablet, 1 tablet bid